Accolade Stockholders Approve Merger Between Accolade and Transcarent

Core Viewpoint - Accolade stockholders have approved the merger with Transcarent, with the transaction expected to close in the second quarter of 2025, subject to regulatory approvals [1][2]. Group 1: Merger Details - The merger was approved during a special meeting of Accolade stockholders [1]. - The transaction is anticipated to be completed in the second quarter of 2025, pending customary closing conditions and state regulatory approvals [2]. - Following the merger, Accolade will transition to a privately held company, and its common stock will no longer be publicly traded [2]. Group 2: Advisory Information - Evercore is the exclusive financial advisor for Transcarent, while Morgan Stanley & Co LLC serves as the financial advisor for Accolade [3]. - Legal advisory for Transcarent is provided by Wilson Sonsini Goodrich & Rosati, and Cooley LLP advises Accolade [3]. Group 3: Company Profiles - Accolade is a Personalized Healthcare company that offers a range of healthcare solutions, achieving consumer satisfaction ratings exceeding 90% [4]. - Transcarent focuses on providing accessible, high-quality healthcare experiences, utilizing generative AI for benefits navigation and clinical guidance [5][6].